Monthly shot shows promise in taming debilitating chronic migraines

NCT ID NCT03867201

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested whether a monthly injection called erenumab could safely reduce the number of migraine days for adults with chronic migraine. Over 550 participants were randomly assigned to receive either the real injection or a placebo shot for 12 weeks. The main goal was to see if the treatment could cut down monthly migraine days and related disability compared to the placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Beijing, Beijing Municipality, 100000, China
Novartis Investigative Site

Beijing, Beijing Municipality, 100039, China
Novartis Investigative Site

Xiamen, Fujian, 361001, China
Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Shijiazhuang, Hebei, 500051, China
Novartis Investigative Site

Zhengzhou, Henan, 450052, China
Novartis Investigative Site

Jingzhou, Hubei, 434020, China
Novartis Investigative Site

Wuhan, Hubei, 430060, China
Novartis Investigative Site

Changsha, Hunan, 410003, China
Novartis Investigative Site

Changsha, Hunan, 410008, China
Novartis Investigative Site

Nanjing, Jiangsu, 210008, China
Novartis Investigative Site

Nanjing, Jiangsu, 210029, China
Novartis Investigative Site

Suzhou, Jiangsu, 215004, China
Novartis Investigative Site

Wuxi, Jiangsu, 214002, China
Novartis Investigative Site

Changchun, Jilin, 130021, China
Novartis Investigative Site

Changchun, Jilin, 130041, China
Novartis Investigative Site

Shenyang, Liaoning, 100016, China
Novartis Investigative Site

Yinchuan, Ningxia, 100039, China
Novartis Investigative Site

Jinan, Shandong, 250013, China
Novartis Investigative Site

Xian, Shanxi, 710061, China
Novartis Investigative Site

Chengdu, Sichuan, 610041, China
Novartis Investigative Site

Kunming, Yunnan, 650000, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310006, China
Novartis Investigative Site

Hangzhou, Zhejiang, 310016, China
Novartis Investigative Site

Beijing, 065001, China
Novartis Investigative Site

Beijing, 100050, China
Novartis Investigative Site

Chongqing, 400016, China
Novartis Investigative Site

Qingdao, 266000, China
Novartis Investigative Site

Shanghai, 200040, China
Novartis Investigative Site

Shanghai, 200080, China
Novartis Investigative Site

Nashik, Maharashtra, 422005, India
Novartis Investigative Site

Lucknow, Uttar Pradesh, 226014, India
Novartis Investigative Site

Dehradun, Uttarakhand, 248001, India
Novartis Investigative Site

Seberang Jaya, Pulau Pinang, 13700, Malaysia
Novartis Investigative Site

Sungai Buloh, Selangor, 47000, Malaysia
Novartis Investigative Site

Kuala Terengganu, Terengganu, 20400, Malaysia
Novartis Investigative Site

Kuala Lumpur, 59100, Malaysia
Novartis Investigative Site

Manila, National Capital Region, 1000, Philippines
Novartis Investigative Site

Pasig, 1605, Philippines
Novartis Investigative Site

Singapore, 169608, Singapore
Novartis Investigative Site

Hwaseong-si, Gyeonggi-do, 18450, South Korea
Novartis Investigative Site

Seoul, Korea, 08308, South Korea
Novartis Investigative Site

Gyeonggi-do, 11765, South Korea
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 03181, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 139-711, South Korea
Novartis Investigative Site

Chiayi City, 60002, Taiwan
Novartis Investigative Site

Taichung, 40447, Taiwan
Novartis Investigative Site

Taichung County, 411743, Taiwan
Novartis Investigative Site

Tainan, 701, Taiwan
Novartis Investigative Site

Tainan, 71004, Taiwan
Novartis Investigative Site

Taipei, 10449, Taiwan
Novartis Investigative Site

Taipei, 11217, Taiwan
Novartis Investigative Site

Taipei, 114, Taiwan
Novartis Investigative Site

Taoyuan District, 33305, Taiwan
Novartis Investigative Site

Bangkok, THA, 10400, Thailand
Novartis Investigative Site

Khon Kaen, THA, 40002, Thailand
Novartis Investigative Site

Bangkok, 10330, Thailand
Novartis Investigative Site

Bangkok, 10400, Thailand
Novartis Investigative Site

Chiang Mai, 50200, Thailand
Novartis Investigative Site

Ho Chi Minh City, VNM, 700000, Vietnam
Novartis Investigative Site

Hanoi, 100000, Vietnam

Conditions

Explore the condition pages connected to this study.

MIGRAINE